Abstract
BackgroundImmune-related adverse events (irAEs) are serious side effects of immune checkpoint inhibitors (ICIs) for patients with advanced cancer. Understanding the epidemiology and risk factors for severe irAEs would be beneficial...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
